Skip to main content
. 2023 Feb 1;15(3):918. doi: 10.3390/cancers15030918

Figure 3.

Figure 3

BRAF inhibitors decrease the level of the RIPK4 protein in BRAFV600 and BRAFWT cells. (a) Viability of melanoma cells (A375, WM266.4, BLM) and LoVo cells treated with vemurafenib (PLX; 10 µM) and dabrafenib (GSK; 10 nM) at 24–72 h using the MTT assay. (b,c) Western blot images showing the levels of P-ERK1/2, ERK1/2 and RIPK4 proteins in cells after treatment with (b) vemurafenib (PLX; 10 µM) and dabrafenib (GSK; 10 nM) for 48 h or (c) U0126 (5 µM). GAPDH is the loading control. Each bar represents the mean ± SD of three biological replicates. Statistical analysis was performed using the Student’s t test. * p < 0.05 and ** p < 0.01 were considered significant.